• 1
    Sehgal PB, Wang L, Rayanade RJ, et al. Interleukin-6-type cytokines. Ann NY Acad Sci. 1995; 762: 114.
  • 2
    Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (SF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986; 324: 7376.
  • 3
    Matsusaka T, Fujiwara K, Nishio Y, et al. Transcription factors NF-IL6 and NF-kB synergistically activate transcription of the inflammatory cytokines, interleukin-6 and interleukin-8. Proc Natl Acad Sci USA. 1993; 90: 1019310197.
  • 4
    Kinoshita S, Akira S, Kishimoto T. A member of the C/EBP family, NF-IL6β, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proc Natl Acad Sci USA. 1992; 89: 14731476.
  • 5
    Wang L, Rayanade RJ, Garcia D, et al. Modulation of interleukin-6 plasma protein secretion in hepatoma cells by p53 species. J Biol Chem. 1995; 270: 2315923165.
  • 6
    Angelo LS, Talpaz M, Kurzrock R. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53. Cancer Res. 2002; 62: 932940.
  • 7
    Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992; 258: 593597.
  • 8
    Yasukawa K, Saito T, Fukunaga T, et al. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem. 1990; 108: 673676.
  • 9
    Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990; 63: 11491157.
  • 10
    Ward LD, Howlett GJ, Discolo G, et al. High affinity interleukin-6 receptor is an hexameric complex consisting of 2 molecules each of interleukin-6, interleukin-6 receptor, and gp130. J Biol Chem. 1994; 269: 286289.
  • 11
    Grotzinger J, Kernebeck T, Kallen K-J, et al. IL-6 type cytokine receptor complexes: hexamer, tetramer, or both? Biol Chem. 1999; 380: 803813.
  • 12
    Novick D, Engelmann H, Wallach D, et al. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989; 170: 14091414.
  • 13
    Montero-Julian FA. The soluble IL-6 receptors: serum levels and biological function. Cell Mol Biol. 2001; 47: 583597.
  • 14
    Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signaling in chronic inflammation and cancer. Scand J Immunol. 2006; 63: 321329.
  • 15
    Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 2005; 28: 187196.
  • 16
    Stahl N, Boulton TG, Farruggella T, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science. 1994; 263: 9295.
  • 17
    Ihle JN, Kerr I. Jaks and Stats in signalling by the cytokine receptor superfamily. Trends Genet. 1995; 11: 6974.
  • 18
    Zhon Z, Wen Z, Darnell JEJr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994; 264: 9598.
  • 19
    Nakajima T, Kinoshita S, Sasagawa T, et al. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA. 1993; 90: 22072211.
  • 20
    Chen GK, Sale S, Tan T, et al. CCAAT/enhancer-binding protein beta (nuclear factor for interleukin-6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. Mol Pharmacol. 2004; 65: 906916.
  • 21
    Kayacan O, Karnak D, Beder S, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol. 2006; 29: 328335.
  • 22
    Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278: 4577745784.
  • 23
    Flower L, Gray R, Pinkney J, et al. Stimulation of interleukin-6 release by interleukin-1beta from isolated human adipocytes. Cytokine. 2003; 21: 3237.
  • 24
    John GR, Lee SC, Brosnan CF. Cytokines: powerful regulators of glial cell activation. Neuroscientist. 2003; 9: 1022.
  • 25
    Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54: 28172829.
  • 26
    Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818825.
  • 27
    Tackey E, Lipsky PE, Illei GG, et al. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004; 13: 339343.
  • 28
    Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut. 2005; 54: 488495.
  • 29
    Yamamoto T, Saniabadi AR, Umegae S, et al. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis. 2006; 12: 719726.
  • 30
    Kofler S, Nicket T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (London). 2005; 108: 205213.
  • 31
    van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am. 1999; 13: 413426.
  • 32
    Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004; 10: 201222.
  • 33
    Ferrari SL, Rizzoli R. Gene variants for osteoporosis and their pleiotropic effects in aging. Mol Aspects Med. 2005; 26: 145167.
  • 34
    Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000; 51: 245270.
  • 35
    Cacquevel M, Lebeurrier N, Cheenne S, et al. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets. 2004; 5: 529534.
  • 36
    Miljkovic DJ, Drulovic J, Trajkovic V, et al. Nitric oxide metabolites and interleukin-6 in cerebrospinal fluid from multiple sclerosis patients. Eur J Neurol. 2002; 9: 413418.
  • 37
    Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des. 2005; 11: 9991016.
  • 38
    Licastro F, Grimaldi LM, Bonafe M, et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging. 2003; 24: 921926.
  • 39
    Ludwig H, Nachbaur DM, Fritz E, et al. Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991; 77: 27942795.
  • 40
    Seymour JF, Talpaz M, Cabanillas F, et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995; 13: 575582.
  • 41
    Berek JS, Chung C, Kaldi K, et al. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991; 164: 10381043.
  • 42
    Plante M, Rubin SC, Wong G, et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994; 73: 18821888.
  • 43
    Twillie DA, Eisenberger MA, Carducci MA, et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995; 45: 542549.
  • 44
    Blay J-Y, Negrier S, Cobaret V, et al. Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992; 52: 33173322.
  • 45
    Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993; 53: 21182122.
  • 46
    Sehgal PB. Interleukin-6-type cytokines in vivo: regulated bioavailability. Proc Soc Exp Biol Med. 1996; 213: 238247.
  • 47
    Iacopetta B, Grieu F, Joseph D. The −174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer. 2004; 90: 419422.
  • 48
    Smith KC, Bateman AC, Fussell HM, et al. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet. 2004; 31: 167173.
  • 49
    Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus non-inflammatory breast cancer by real-time reverse transcriptase PCR gene expression quantification. Clin Cancer Res. 2004; 10: 79657971.
  • 50
    Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY. Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer. 2002; 2: 311315.
  • 51
    Danforth DNJr, Sgagias MK. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res. 1993; 53: 15381545.
  • 52
    Shen WH, Zhou JH, Broussard SR, Freund GG, Dantzer R, Kelley KW. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res. 2002; 62: 47464756.
  • 53
    Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001; 61: 88518858.
  • 54
    Selander KS, Li L, Watson L, et al. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of STAT3 and inhibits in vivo malignancy. Cancer Res. 2004; 64: 69246933.
  • 55
    Singh A, Purohit A, Ghilchik MW, Reed MJ. The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocr Relat Cancer. 1999; 6: 139147.
  • 56
    Salgado R, Benoy I, Van Dam P, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003; 103: 642646.
  • 57
    Chavey C, Bibeau F, Gourgou-Bourgade S, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res [serial online]. 2007; 9: R15.
  • 58
    Barak V, Kalickman I, Nisman B. Changes in cytokine production of breast cancer patients treated with interferons. Cytokine. 1998; 10: 977983.
  • 59
    Lahm H, Petral-Malec D, Yilmaz-Ceyhan A, et al. Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and −6 and antagonistic effects of transforming growth factor beta 1. Eur J Cancer. 1992; 28: 18941899.
  • 60
    Schneider MR, Hoeflich A, Fischer JR, et al. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 2000; 151: 3138.
  • 61
    Rabau M, Kashtan H, Baron S, et al. Inhibition of CT-26 murine adenocarcinoma growth in the rectum of mice treated with recombinant human interleukin-6. J Immunother Emphasis Tumor Immunol. 1994; 15: 257264.
  • 62
    Biarc J, Nguyen IS, Pini A, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcuc infantarius (formerly S. bovis). Carcinogenesis. 2004; 25: 14771484.
  • 63
    Isomoto H, Mott JL, Kobayashi S, et al. Sustained signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007; 132: 384396.
  • 64
    Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 2007; 282: 82568264.
  • 65
    De Vita F, Romano C, Orditura M, et al. Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res. 2001; 21: 4552.
  • 66
    Tchirkov A, Khalil T, Chautard E, et al. Interleukin-6 gene amplification and shortened survival in glioblastoma patients. Br J Cancer. 2007; 96: 474476.
  • 67
    Chaudry IH, O'Donovan DG, Brenchley PE, et al. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology. 2001; 39: 409415.
  • 68
    Weissenberger J, Loeffler S, Kappeler A, et al. IL-6 is required for glioma development in a mouse model. Oncogene. 2004; 23: 33083316.
  • 69
    Loeffler S, Berengere F, Weis J, Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer. 2005; 115: 202213.
  • 70
    Emilie D, Leger-Ravet MB, Devergne O, et al. Intratumoral production of IL-6 in B cell chronic lymphocytic leukemia and B lymphomas. Leuk Lymphoma. 1993; 11: 411417.
  • 71
    Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001; 97: 256263.
  • 72
    Koistinen P, Saily M, Poromaa N, et al. Complex effects of interleukin-6 on clonogenic blast cell growth in acute myeloblastic leukemia. Acta Haematol. 1997; 98: 1421.
  • 73
    Bihl M, Tamm M, Nauck M, et al. Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol. 1998; 19: 606612.
  • 74
    Scott HR, McMillan DC, Crilly A, et al. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer. 1996; 73: 15601562.
  • 75
    Katsumata N, Eguchi K, Fukuda M, et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res. 1996; 2: 553559.
  • 76
    Alexandrakis MG, Coulocheri SA, Bouros D, Mandalaki K, Karkavitsas N, Eliopoulos GD. Evaluation of inflammatory cytokines in malignant and benign pleural effusions. Oncol Rep. 2000; 7: 13271332.
  • 77
    Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine. 2002; 20: 304311.
  • 78
    Foss HD, Herbst H, Oelmann E, et al. Lymphotoxin, tumour necrosis factor, and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. Br J Haematol. 1993; 84: 627635.
  • 79
    Yee C, Biondi A, Wang XH, et al. A possible autocrine role for interleukin-6 in 2 lymphoma cell lines. Blood. 1989; 74: 798804.
  • 80
    Ruff KR, Puetter A, Levy LS. Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-b1 and IL-6. BMC Cancer [serial online]. 2007; 7: 35.
  • 81
    Hideshima T, Chauhan D, Teoh G, et al. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res. 2000; 6: 11801189.
  • 82
    Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of 6 genes. N Engl J Med. 2004; 350: 18281837.
  • 83
    Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood. 2004; 103: 32163221.
  • 84
    Fayad L, Cabanillas F, Talpaz M, et al. High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma. 1998; 30: 563571.
  • 85
    Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989; 74: 13601367.
  • 86
    Emilie D, Wijdenes J, Gisselbrecht C, et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. Blood. 1994; 84: 24722479.
  • 87
    Haddad E, Paczesny S, Leblond V, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood. 2001; 97: 15901597.
  • 88
    Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000; 95: 5661.
  • 89
    Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment in multicentric Castleman's disease. Blood. 2005; 106: 26272632.
  • 90
    Kurzrock R, Voorhees P, Fayad L, et al. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in patients with selected hematologic malignancies. J Clin Oncol (Meeting Abstracts). 2006; 24. Abstract 2513.
  • 91
    VanRhee F, Fayad L, Borghaei, H, et al. CNTO 328, an anti-interleukin-6 monoclonal antibody—preliminary results of subjects with Castleman's disease from a phase 1 study in selected hematological malignancies. Blood (ASH Annual Meeting Abstracts). 2006; 108. Abstract 2728.
  • 92
    Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993; 120: 12811288.
  • 93
    Sun WH, Kreisle RA, Phillips AW, et al. In vivo and in vitro characteristics of interleukin-6-transfected B16 melanoma cells. Cancer Res. 1992; 52: 54125415.
  • 94
    Komyod W, Bohm M, Metze D, Heinrich PC, Behrmann I. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res. 2007; 5: 271281.
  • 95
    Mackiewicz A, Wiznerowicz M, Roeb E, et al. Interleukin-6-type cytokines and their receptors for gene therapy of melanoma. Ann NY Acad Sci USA. 1995; 762: 361373.
  • 96
    de Galdeano G, Boyano D, Smith-Zubiaga I, et al. Involvement of interleukin-6 in the biology and metastatic activity of B16F10 melanoma cells. Eur Cytokine Netw. 1998; 9: 187192.
  • 97
    Mouawad R, Rixe O, Meric JB, et al. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther. 2002; 7: 151156.
  • 98
    Mouawad R, Soubrane C, Rixe O, Khayat D, Spano JP. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res. 2006; 16: 335340.
  • 99
    Jourdan M, Zhang XG, Portier M, et al. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol. 1991; 147: 44024407.
  • 100
    Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine. 2001; 16: 7986.
  • 101
    Klein B, Lu ZY, Gu ZJ, et al. Interleukin-10 and Gp130 cytokines in human multiple myeloma. Leuk Lymphoma. 1999; 34: 6370.
  • 102
    Gaillard JP, Liautard J, Klein B, et al. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines. Eur J Immunol. 1997; 27: 33323340.
  • 103
    Diamant M, Hansen MB, Rieneck K, et al. Differential interleukin-6 (IL-6) responses of 3 established myeloma cell lines in the presence of soluble human IL-6 receptors. Leuk Res. 1996; 20: 291301.
  • 104
    Ishikawa H, Tsuyama N, Obata M, Kawano M. Mitogenic signals initiated via interleukin-6 receptor complexes in cooperation with other transmembrane molecules in myelomas. J Clin Exp Hematol. 2006; 46: 5566.
  • 105
    Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 2002; 100: 194199.
  • 106
    Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000; 60: 67636770.
  • 107
    Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000; 95: 26302636.
  • 108
    Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumors. Cancer Res. 2007; 67: 871875.
  • 109
    Solary E, Guiguet M, Zeller V, et al. Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am J Hematol. 1992; 39: 163171.
  • 110
    Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood. 1995; 85: 765771.
  • 111
    Kyrtsonis MC, Dedoussis G, Zervas C, et al. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br J Haematol. 1996; 93: 398400.
  • 112
    Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003; 22: 83868393.
  • 113
    Bataille R, Barlogie B, Lu ZY, et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995; 86: 685691.
  • 114
    Moreau P, Harousseau JL, Wijdenes J, et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol. 2000; 109: 661664.
  • 115
    Rossi JF, Fegueux N, Lu ZY, et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 2005; 36: 771779.
  • 116
    Watson JM, Sensintaffar JL, Berek JS, et al. Constitutive production of interleukin-6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res. 1990; 50: 69596965.
  • 117
    Asschert JG, De Vries EG, DeJong S, Withoff S, Vellenga E. Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1. Int J Cancer. 1999; 81: 236242.
  • 118
    Sutherland KD, Lindeman GJ, Choong DY, et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 2004; 23: 77267733.
  • 119
    Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst. 2002; 94: 617629.
  • 120
    Rabinovich A, Medina L, Piura B, Segal S, Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res. 2007; 27: 267272.
  • 121
    Rosen DG, Mercado-Uribe I, Yang G, et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer. 2006; 107: 27302740.
  • 122
    van der Zee AG, de Cuyper EM. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer. 1995; 75: 10041009.
  • 123
    Garg R, Wollan M, Galic V, et al. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006; 103: 793796.
  • 124
    Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993; 11: 499506.
  • 125
    Bellone G, Carbone A, Smirne C, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol. 2006; 177: 34483460.
  • 126
    Tang RF, Wang SX, Zhang FR, et al. Interleukin-1alpha, 6 regulate the secretion of vascular endothelial growth factor A, C in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2005; 4: 460463.
  • 127
    Ebrahimi B, Tucker SL, Li D, et al. Cytokines in pancreatic cancer: correlation with phenotypic characteristics and prognosis. Cancer. 2004; 101: 27272736.
  • 128
    Bartsch R, Woehrer S, Raderer M, Hejna M. Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. Anticancer Res. 2006; 26: 31873190.
  • 129
    Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol. 2001; 159: 21592165.
  • 130
    Cavarretta IT, Neuwirt H, Untergasser G, et al. The antiapoptotic effect of an IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene. 2007; 26: 28222832.
  • 131
    Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int. 2003; 91: 545553.
  • 132
    Wallner L, Dai J, Escara-Wilke J, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res. 2006; 66: 30873095.
  • 133
    Steiner H, Cavaretta IT, Moser PL, et al. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate. 2006; 66: 17441752.
  • 134
    Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer. 1999; 85: 134144.
  • 135
    Flowers LO, Subramaniam PS, Johnson HM. A SOCS-1 peptide mimetic inhibits both constitutive and IL-6-induced activation of STAT3 in prostate cancer cells. Oncogene. 2005; 24: 21142120.
  • 136
    Drachenberg DE, Elgamal AA, Rowbotham R, et al. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999; 41: 127133.
  • 137
    Culig Z, Steiner H, Bartsch G, et al. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem. 2005; 95: 497505.
  • 138
    Kuroda K, Nakashima J, Kanao K, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology. 2007; 69: 113117.
  • 139
    Miki S, Iwano M, Miki Y, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989; 250: 607610.
  • 140
    Chang SG, Shin C, Rho SK, et al. Cytokine production in primary histoculture by human normal kidney, renal cell carcinoma and benign renal angiomyolipoma tissues. Anticancer Res. 1998; 18: 41954200.
  • 141
    Alberti L, Bachelot T, Duc A, et al. A spliced isoform of interleukin-6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor. Cancer Res. 2005; 65: 25.
  • 142
    Cabillic F, Bouet-Toussaint F, Toutirais O, et al. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. Clin Exp Immunol. 2006; 146: 518523.
  • 143
    Negrier S, Perol D, Menetrier-Caux C, et al. Groupe Francais d'Immunotherapie. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol. 2004; 22: 23712378.
  • 144
    Cardillo MR, Ippoliti F. Interleukin-6, interleukin-10, and heat shock protein-90 expression in renal epithelial neoplasia and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol. 2007; 20: 3746.
  • 145
    Schuler M, Bruntsch U, Spath-Schwalbe E, et al. Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study. Eur J Cancer. 1998; 34: 754756.
  • 146
    Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer. 1997; 72: 424430.
  • 147
    Strassman G, Fong M, Kenney JS, et al. Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest. 1992; 89: 16811684.
  • 148
    Barton BE, Murphy TF. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine. 2001; 16: 251257.
  • 149
    Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin- (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 B1 background and eicosanoid-dependent cachexia. Cancer Res. 2000; 60: 54885493.
  • 150
    Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 1999; 11: 8086.
  • 151
    Pfitzenmaier J, Vassella R, Higano CS, et al. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003; 97: 12111216.
  • 152
    Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6 inhibits human tumor-induced cachexia in nude mice. Int J Cancer. 2004; 111: 592595.
  • 153
    Lu ZY, Brailly H, Wijdenes J, et al. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood. 1995; 86: 31233131.
  • 154
    Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003; 9: 46534665.
  • 155
    Yokota S, Miyamae T, Imagawa T. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005; 28: 231238.
  • 156
    Paul-Pletzer K. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today. 2006; 42: 559576.
  • 157
    Montero-Julian FA, Gautherot E, Wijdenes J, et al. Pharmacokinetics of interleukin-6 during therapy with anti-interleukin-6 monoclonal antibodies: enhanced clearance of interleukin-6 by a combination of 3 anti-interleukin-6 antibodies. J Interferon Res. 1994; 14: 301302.
  • 158
    Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61: 30713076.
  • 159
    Wigmore SJ, Fearon KC, Maingay JP, et al. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression in interleukin-6. Clin Sci. 1997; 92: 215221.
  • 160
    Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated anti-apoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007; 109: 22932302.
  • 161
    Amit-Vazina M, Shishodia S, Harris D, et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005; 93: 7080.
  • 162
    Choudari SR, Khan MA, Harris G, et al. Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther. 2007; 6: 112121.
  • 163
    Braiteh FS, Yao J, Camacho LH, et al. Phase I study of the safety and efficacy of atiprimod, a novel azaspirine, for patients with advanced cancer. J Clin Oncol (Meeting Abstracts). 2006; 24. Abstract 13050.
  • 164
    Enomoto A, Rho MC, Fukami A, et al. Suppression of cancer cachexia by 20S, 21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun. 2004; 323: 10961102.
  • 165
    Matsumoto G, Namekawa J, Muta M, et al. Targeting of nuclear factor kappaB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res. 2005; 11: 12871293.
  • 166
    Lin M, Rose-John S, Grotzinger J, Conrad U, Scheller J. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling. Biochem J. 2006; 398: 577583.
  • 167
    Rose-John S, Schooltink H. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res. 2007; 174: 5766.
  • 168
    Ciapponi L, Maione D, Scoumanne A, et al. Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat Biotechnol. 1997; 15: 9971001.